Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Liz Hudson Office Manager ADDRESS Meditrina Building Babraham Research Campus Cambridge CB22 3AT TELEPHONE +44 1223 497415 FAX +44 1223 832177 EMAIL liz.hudson @bicycletherapeutics.com YEAR FOUNDED 2009 Bicycle Therapeutics Limited www.bicycletherapeutics.com FINANCIAL SUMMARY Funded by £3.95m seed investment with four blue chip investors: • Atlas Ventures • Novartis Venture Funds • SR One • SV Life Sciences COMPANY PROFILE Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, UK developing a novel technology which uses biological selection methods to identify molecules which combine features of small molecular weight drugs and and biopharmaceuticals. The technology allows the identification of highly constrained peptides with high potency and selectivity against the target of interest. Bicycle peptides have properties that overcome many of the deficiencies of previous generations of peptide based drugs and the Bicycle libraries offer a vast diversity with which to interrogate target space. Bicycle technology is based on the work performed at the MRC Laboratory of Molecular Biology in Cambridge by the scientific founders of the company, Prof Christian Heinis and Sir Gregory Winter. The company was founded in July 2009 and received initial seed funding from Atlas Venture and Novartis Venture Fund who were subsequently joined by SVLS and SR One to complete the seed phase syndicate. MANAGEMENT Dr Rolf Guenther, CEO Dr John Tite, CSO t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Tom Kronbach, PhD Chief Executive Officer Viktor Viehweg Chief Financial Officer ADDRESS BioCrea GmbH Meissner Strasse 191 01445 Radebeul Germany TELEPHONE +49 351 4043 3374 Tom Kronbach +49 351 4043 3332 Viktor Viehweg +49 351 4043 3252 FAX +49 351 4043 3216 EMAIL infobiocrea@biocrea.com tom.kronbach@biocrea.com viktor.viehweg@biocrea.com YEAR FOUNDED 2010 BioCrea GmbH www.biocrea.com FINANCIAL SUMMARY Private Company, initial funding by Biotie Therapies, which has a minority stake. COMPANY PROFILE biocrea discovers and develops novel drugs for the treatment of debilitating CNS diseases such as schizophrenia or Huntington’s disease. The company’s team has an exceptional track record in the development of CNS drug candidates and has partnered extensively with major pharmaceutical companies such as Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. biocrea is based in Radebeul, Germany. MANAGEMENT Dr Thomas Kronbach, Chief Executive Officer Viktor Viehweg, Chief Financial Officer Dr Martin Gunthorpe, Chief Scientific Officer Prof Simon Ward, Executive Vice President Chemistry & Development t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35: CONTACT Mr Richard Godfrey Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?